The description of the disease called trigger finger was done by Notta, a French physician as early as 1850 [1]. Histological studies have shown metaplasia of cartilage like cells within the A1 pulley area of the flexor tendon sheath with no real evidence of inflammation [2]. It is a common hand condition seen in patients with diabetes and they are sub group known to develop recurrences after primary treatment. Howard et al. [3] in 1953 described the first use of a locally injected steroid into the tendon sheath as treatment, while in 1958 Lorthinor et al. described the first surgical decompression of the constriction [4]. Both forms of management are still practiced as primary management of the trigger finger. Numerous studies [5] have been done showing the obvious benefits of steroid injections in trigger finger treatment. The most commonly employed technique is to give a mixed solution of lignocaine and methyl prednisolone or triamcinolone administered through a palmar route directly into the palpable nodule at the A1 pulley area, withdrawing the needle from the tendon to infiltrate the tendon sheath [6]. Some techniques describe a similar approach, but with the drug administered on the far side of the tendon [5], between the tendon and the metacarpal bone. One of the obvious disadvantages of the procedure is pain. As the palmar skin has a high density of sensory receptors, some authors describe the use of a local anaesthetic injection first followed by the steroid injection through the same needle to minimize pain during the procedure. Carlson CS & Curtis RM described a technique of infiltration of the flexor sheath by a mid axial route in 1984 [7] for flexor tenosynovitis. This technique has been used in all patients requiring steroid injection for trigger finger.
Read full abstract